European urology最新文献

{"title":"Re: Frédéric Panthier, Vineet Gauhar, Eugenio Ventimiglia, Jia-Lun Kwok, Etienne Xavier, Olivier Traxer. Rethinking Stone-free Rates and Surgical Outcomes in Endourology: A Point of View from PEARLS Members. Eur Urol. 2024;86:198–199","authors":"Roger L. Sur","doi":"10.1016/j.eururo.2024.08.039","DOIUrl":"10.1016/j.eururo.2024.08.039","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Page e19"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Feng Qi’s Letter to the Editor re: Niklas Klümper, Viktor Grünwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer. Eur Urol. 2024;86:388–390","authors":"Niklas Klümper , Markus Eckstein","doi":"10.1016/j.eururo.2024.09.019","DOIUrl":"10.1016/j.eururo.2024.09.019","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages e17-e18"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology","authors":"Sandy Figiel ,&nbsp;Anthony Bates ,&nbsp;David A. Braun ,&nbsp;Renu Eapen ,&nbsp;Markus Eckstein ,&nbsp;Brandon J. Manley ,&nbsp;Matthew I. Milowsky ,&nbsp;Tom J. Mitchell ,&nbsp;Richard J. Bryant ,&nbsp;John P. Sfakianos ,&nbsp;Alastair D. Lamb","doi":"10.1016/j.eururo.2024.08.025","DOIUrl":"10.1016/j.eururo.2024.08.025","url":null,"abstract":"<div><div>New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within and around individual malignancies, offering novel insights into disease development, progression, diagnosis, and treatment. They enable tracking of clonal phylogenetics in situ and immune-cell interactions in the tumour microenvironment. A whole transcriptome/genome/proteome-level spatial analysis is hypothesis generating, particularly in the areas of risk stratification and precision medicine. Current challenges include reagent costs, harmonisation of protocols, and computational demands. Nonetheless, the evolving landscape of the technology and evolving machine learning applications have the potential to overcome these barriers, pushing towards a future of personalised cancer therapy, leveraging detailed spatial cellular and molecular data.</div></div><div><h3>Patient summary</h3><div>Tumours are complex and contain many different components. Although we have been able to observe some of these differences visually under the microscope, until recently, we have not been able to observe the genetic changes that underpin cancer development. Scientists are now able to explore molecular/genetic differences using approaches such as “spatial transcriptomics” and “spatial proteomics”, which allow them to see genetic and cellular variation across a region of normal and cancerous tissue without destroying the tissue architecture. Currently, these technologies are limited by high associated costs, and a need for powerful and complex computational analysis workflows. Future advancements and results through these new technologies may assist patients and their doctors as they make decisions about treating their cancer.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 8-14"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Andrés Gutiérrez, Julio Cesar Boada, and Sebastián Peña’s Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. 2024;86:400–408","authors":"Pieter Vynckier ,&nbsp;Lieven Annemans ,&nbsp;Monique Roobol","doi":"10.1016/j.eururo.2024.08.028","DOIUrl":"10.1016/j.eururo.2024.08.028","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Page e14"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transporting Testosterone Home: Navigating the Road to Recovery","authors":"Vedang Murthy ,&nbsp;Alan Dal Pra","doi":"10.1016/j.eururo.2024.10.016","DOIUrl":"10.1016/j.eururo.2024.10.016","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 58-59"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis","authors":"Rajvi Goradia ,&nbsp;Firas Abdollah ,&nbsp;Akshay Sood","doi":"10.1016/j.eururo.2024.07.014","DOIUrl":"10.1016/j.eururo.2024.07.014","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 90-91"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: International Survey on Urodynamic Investigations in Women Undergoing Stress Urinary Incontinence Surgery","authors":"Maurizio Serati ,&nbsp;Tufan Tarcan ,&nbsp;Enrico Finazzi Agrò","doi":"10.1016/j.eururo.2024.07.018","DOIUrl":"10.1016/j.eururo.2024.07.018","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 89-90"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies","authors":"Omar El-Taji,&nbsp;Noel W. Clarke","doi":"10.1016/j.eururo.2024.10.005","DOIUrl":"10.1016/j.eururo.2024.10.005","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 27-28"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2024.11.020","DOIUrl":"10.1016/j.eururo.2024.11.020","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages e1-e11"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review","authors":"Edoardo Francini ,&nbsp;Neeraj Agarwal ,&nbsp;Elena Castro ,&nbsp;Heather H. Cheng ,&nbsp;Kim N. Chi ,&nbsp;Noel Clarke ,&nbsp;Joaquin Mateo ,&nbsp;Dana Rathkopf ,&nbsp;Fred Saad ,&nbsp;Bertrand Tombal","doi":"10.1016/j.eururo.2024.09.008","DOIUrl":"10.1016/j.eururo.2024.09.008","url":null,"abstract":"<div><h3>Background and objective</h3><div>Recently, research on treatment intensification has gathered momentum, and three novel therapy combinations were approved for metastatic castration-resistant prostate cancer (mCRPC). This systematic review summarizes the current and emerging evidence around intensified strategies for mCRPC and provides guidance for an ideal therapeutic sequencing.</div></div><div><h3>Methods</h3><div>Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines were followed to perform this review. PubMed, EMBASE, Web of Science, Cochrane Library, ClinicalTrials.gov, and major international societies’ online proceedings were searched comprehensively until May 15, 2024, for terms related to treatment intensification and sequencing for mCRPC.</div></div><div><h3>Key findings and limitations</h3><div>Overall, 28 clinical trials and 24 ongoing studies of intensification treatments were included in this review. Algorithms of optimal sequencing of approved treatments for mCRPC were outlined according to the use of androgen receptor pathway inhibitors (ARPIs) with or without docetaxel for earlier disease states. In first line, poly(ADP-ribose) polymerase inhibitor + ARPI combinations improve radiographical progression-free survival (rPFS), particularly for those with BRCA1/2 alterations. The AKT inhibitor combination of ipatasertib + abiraterone extends rPFS in those with PTEN loss or PIK3CA/AKT1/PTEN alterations. In those with two or more risk factors for early progression on enzalutamide, radionuclide 177-Lu-PSMA-617 + enzalutamide prolongs progression-free survival. Ongoing research of intensified approaches for mCRPC, and available and potential predictive and prognostic biomarkers are discussed.</div></div><div><h3>Conclusions and clinical implications</h3><div>Recent approvals and ongoing investigations of single agents and intensification approaches will keep transforming the mCRPC treatment landscape. Improvement of patient profiling applying recognized genomic, molecular, and clinical predictive and prognostic indicators is fundamental to optimize sequential use of available therapies.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Pages 29-46"},"PeriodicalIF":25.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}